Home > DARE Reviews > A systematic review of atypical...
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination (UK); 1995-.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].

A systematic review of atypical antipsychotic drugs in schizophrenia

Review published: 2003.

Bibliographic details: Bagnall A M, Jones L, Ginnelly L, Lewis R, Glanville J, Gilbody S, Davies L, Torgerson D, Kleijnen J.  A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technology Assessment 2003; 7(13): 1-204. [PubMed: 12925268]

Quality assessment

This review assessed the safety and cost-effectiveness of 'atypical' antipsychotic drugs in patients with schizophrenia. The authors concluded that the evidence was limited and should be treated with caution. Generally, none of the eight drugs of interest were found to be more effective than the others, with one exception. The authors' cautious conclusions are likely to be reliable. Full critical summary

CRD has determined that this article meets the DARE scientific quality criteria for a systematic review.

Copyright © 2012 University of York.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...